Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Down 33.8% in July

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 6,859 shares, a decrease of 33.8% from the June 30th total of 10,359 shares. Based on an average trading volume of 6,436 shares, the short-interest ratio is currently 1.1 days.

Defence Therapeutics Stock Down 4.2%

DTCFF stock opened at $0.28 on Friday. Defence Therapeutics has a one year low of $0.25 and a one year high of $0.78. The company has a fifty day moving average price of $0.34 and a two-hundred day moving average price of $0.39.

Defence Therapeutics Company Profile

Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.

The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.